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Introduction: The introduction of targeted therapies in renal cell carcinoma has significantly 
improved its prognosis and treatment outcomes in recent years. Such treatment options are 
targeted therapies of the vascular endothelial growth factor (VEGF) pathway and the mam-
malian target of the rapamycin pathway. With the use of tyrosine kinase inhibitors (TKIs) and 
mammalian target of the rapamycin inhibitors, overall survival has increased up to 2 years. 
In Turkey, due to applicable reimbursement conditions for patients with metastatic renal cell 
carcinoma (mRCC), interferon use is mandated as a first-line treatment, thus providing infor-
mation on the use of everolimus only after initial interferon and second-line VEGF-targeted 
treatments such as VEGF-TKI.
Patients and methods: To provide a first real-life data set in Turkey, we conducted a prospec-
tive, non-interventional, observational study and assessed the efficacy and safety of everolimus 
after two lines of treatment including interferon. A total of 100 patients with histologically 
confirmed mRCC were enrolled in the study from 11 centers between June 2012 and March 2014 
(70 males and 30 females). Efficacy was assessed on the basis of progression-free survival and 
overall survival; safety of everolimus was assessed on the basis of adverse event occurrence.
Results: The study results showed that the median progression-free survival with everolimus 
treatment was 8.1 months (95% CI: 5.1–11.1) and the median overall survival was 17.6 months 
(95% CI: 10.1–25.1), thus indicating a better overall response based on survival durations than 
those from the randomized Phase III REnal Cell cancer treatment with Oral RAD001 given 
Daily study results (4.9 and 14.8 months, respectively).
Conclusion: The study showed that everolimus treatment is a safe and effective treatment 
option in the treatment of mRCC after VEGF-TKI, with an acceptable safety and tolerability 
profile in real-life settings.
Keywords: metastatic renal cell carcinoma, mTOR inhibitors, everolimus, observational study, 
real-life setting, treatment patterns
Introduction
In Turkey, the latest official figures (2013) show higher rates of renal cancer in men, 
7 cases in every 100,000 population, whereas the same rate has been shown to be 
3.4 cases/100,000 standardized population in women and there were higher rates 
of occurrence in the European Union and the USA.1 Approximately 90% of renal 
cancers are renal cell carcinoma (RCC), and the worldwide incidence of renal cancer 
has been increasing by ~2%–4% every year for the last two decades.2,3 During the 
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past two decades, the risk factors for renal cancer such as 
tobacco smoking, heavy alcohol drinking, hypertension, and 
obesity showed a rising tendency, which eventually resulted 
in increasing the risk of malignancy.3 Approximately 30% 
of all patients with RCC have metastatic disease at presenta-
tion, and the available treatments were limited until recently 
because these cancers are relatively resistant to cytotoxic 
chemotherapy.4 However, the introduction of targeted 
therapies has significantly improved treatment outcomes for 
these patients.4–8 These therapies either target the vascular 
endothelial growth factor (VEGF) pathway or the mam-
malian target of the rapamycin (mTOR) pathway, both of 
which are related to the pathogenesis of clear cell metastatic 
RCC (mRCC).6,8,9 With the use of tyrosine kinase inhibitors 
(TKIs) and mTOR inhibitors, survival up to 2 years became 
a reachable goal.6 mTOR is a serine/threonine kinase of the 
PI3K/AKT signaling pathway, and stimulation of this path-
way results in cell proliferation, growth, protein synthesis, 
and angiogenesis. mTOR inhibitors block this signaling 
pathway and improve treatment outcomes in patients with 
advanced and metastatic renal cancer.8,10
Despite the availability of targeted therapies in Turkey, 
due to mandated governmental reimbursement regulations, 
first-line treatment requires interferon use, and treatments that 
target the VEGF pathway are given as second line; therefore, 
mTOR inhibitors are reserved for third-line treatment. In this 
prospective, non-interventional, real-life NOTES (a National, 
multicenter, non-interventional, Observational study on 
TrEatment patternS in patients with metastatic renal cell 
carcinoma) study conducted in Turkey, we aimed to gener-
ate a database on the use of everolimus in the treatment of 
mRCC during routine local practice.
Patients and methods
A multicenter, national, non-interventional, real-life study was 
conducted in Turkey with 11 participating sites and 100 patients 
with mRCC who were enrolled between July 2012 and March 
2014. Patients aged over 18 years with histologically or cyto-
logically confirmed mRCC were eligible. Other enrollment 
criteria were presence of measurable disease according to the 
Response Evaluation Criteria In Solid Tumors criteria, having 
undergone previous systemic therapy following VEGF-TKI 
intolerance or disease progression, and providing consent for 
participation. Patients who were pregnant or lactating or with 
active hepatitis B and C or who were actively participating in 
a clinical or non-interventional study were excluded.
Patients were followed-up for a period of at least 12 months 
after enrollment during their treatment with everolimus. 
Patients were enrolled in the study only after an occurrence of 
VEGF-TKI intolerance or progression of disease. The primary 
objective of the study was to collect information on the mean 
treatment duration with everolimus and observe the main 
demographic and clinical profiles of patients with histologi-
cally confirmed mRCC. Other parameters of interest included 
survival, disease progression, treatment patterns (systemic 
therapies used, required dose changes, and discontinuation of 
therapy), and treatment toxicity. Overall survival (OS), time 
to event analysis, disease progression, and treatment toxicity 
data were analyzed from the onset of first everolimus treatment 
using Kaplan–Meier survival curves. Statistical analyses were 
performed using SPSS software, version 18.1 for Windows 
(IBM Corporation, New York, NY, USA).
ethics
The study protocol was reviewed and approved by an 
independent ethics committee or institutional review board 
(approval from institutional review board at Kecioren Train-
ing and Research Hospital, Turkey, dated April 25, 2012 on 
files) and met the principles of the Declaration of Helsinki. 
The study was conducted in accordance with Good Clinical 
Practice, the principles outlined in the Declaration of Hel-
sinki, and local regulations. All patients provided written 
informed consent before participation in the study.
Results
A total of 100 patients (70% males) were included in the study 
from 11 centers between June 2012 and March 2014. Data 
collection was terminated on June 9, 2015. The median age 
of the patients was 55 years (range, 22–78 years) at diagnosis. 
Histologic confirmations were present for clear cell (n=86) 
and non-clear cell RCC (n=2), and data were not confirmed 
for the rest of the patients (n=12). Sixty-five percent of 
patients were confirmed as having stage IV disease during 
enrollment. Details of the demographic and disease charac-
teristics are presented in Table 1.
The median duration of follow-up was 40.5 months 
(range, 5–164 months); the median OS from the time of 
diagnosis was 49.3 months and from the first-line systemic 
treatment was 19.9 months. The median progression-free 
survival (PFS) and OS with everolimus treatment were 
8.1 months (95% CI: 5.1–11.1) and 17.6 months (95% CI: 
10.1–25.1), respectively.
During the first-line treatment, the majority (84%) of 
patients received interferon treatment in line with the local 
reimbursement conditions, followed by sunitinib, an oral 
multitargeted kinase inhibitor that inhibits certain receptor 
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tyrosine kinases including VEGF receptors (VEGFR type 1, 
2 and 3), platelet-derived growth factor receptors (PDGFR-α 
and PDGFR-β) and c-kit (8%); pazopanib, a second-
generation multitargeted TKI against VEGFR-1, -2, and -3, 
PDGFR-α, PDGFR-β, and c-kit (4%); and sorafenib, an 
inhibitor of receptor tyrosine kinase involved in angiogenesis 
(VEGFR-1, -2, and -3, and PDGFR-β) and tumorigenesis 
(Flt-3, c-Kit, and RET) (3%). The median duration of inter-
feron use as a first-line treatment was 1.7 months (range, 
1–103 months); however, only 27% of patients continued 
interferon beyond 3 months. After cessation of interferon 
therapy, sunitinib was the most frequently used second-line 
therapy (62%) and patients had a median duration of treat-
ment with sunitinib of 9.5 months (range, 1–42.6 months). 
Median duration of treatment with sorafenib and pazopanib 
as a second-line agent was 5.6 and 5.5 months, respectively. 
Overall, the median duration of anti-VEGF treatment was 8.8 
months (range, 1–66 months). The most common cause of 
termination of the anti-VEGF treatment was disease progres-
sion (96%) and intolerance to treatment (4%).
Everolimus treatment was initiated as a third-line treat-
ment in the majority of patients (83%) and the initial dose 
of everolimus was given as 10 mg/day (n=99). Patients 
received everolimus until progression, death, or the end of 
the follow-up period. Best responses to everolimus treatment 
were stable disease in 42%, followed by complete response 
in 2% and partial response in 2%. The objective response 
rate and the disease control rate were calculated as 4% and 
46%, respectively. Disease progression was observed in 22% 
of patients. No follow-up outcomes were available for 32% 
of patients (Table 2).
The median PFS with everolimus treatment was 
8.1 months (95% CI: 5.1–11.1), and the median OS was 
17.6 months (95% CI: 10.1–25.1). One- and 2-year survival 
rates for everolimus were found as 58% and 41%, respec-
tively. Effects of achieved responses to previously used medi-
cations on PFS and OS following everolimus are presented in 
Table 3. A significantly longer PFS was observed in patients 
treated with everolimus who showed longer durations of 
response with interferon and anti-VEGF agents during the 
Table 1 Demographics and medical history at admission for 
evaluation
Characteristics N Percentage
Sex
Male 70 70.0
Female 30 30.0
Age (median years, min–max) 55 22–78
BMI Mean SD
BMi (kg/m2) 26.50 4.81
Smoking status N Percentage
current smoker 7 7
Previous smoker 33 33
never smoked 41 41
Unknown/missing 19 19
Staging at diagnosis (mRCC) N Percentage
stage 1 2 2.0
stage 2 6 6.0
stage 3 12 12.0
stage 4 65 65.0
Unknown 15 15.0
Histologic diagnosis N Percentage
clear cell carcinoma 86 86.0
non-clear cell carcinoma 2 2.0
Not identified/not known 12 12.0
Other risk factors present at diagnosis N
Overweight 20
Obesity 12
hereditary oncocytoma 3
hemodialysis 1
Abbreviations: BMi, body mass index; mrcc, metastatic renal cell carcinoma.
Table 2 survival and response rates with everolimus treatment
Survival outcomes Months (95% CI)
Median PFs 8.1 (5.1–11.1)
Median Os 17.6 (10.1–25.1)
Surviving patients, %
One-year survival 58
Two-year survival 41
Treatment responses with everolimus, %
cr 2
Pr 2
Objective response rate (cr + Pr) 4
sD 42
Disease control rate (cr + Pr + sD) 46
Progression 22
Unknown response 32
Abbreviations: cr, complete response; Os, overall survival; PFs, progression-free 
survival; Pr, partial response; sD, stable disease.
Table 3 The effect of previous treatments on mPFs and mOs 
with everolimus
Treatment Duration of 
response, 
months
mPFS with 
everolimus
mOS with 
everolimus
Duration 
(months)
P-value Duration 
(months)
P-value
interferon ,3 6.3 0.040 12.4 0.108
$3 9.8 20.7
anti-VegF 
(any)
,6
$6
4.2
9.8
0.015 10.7
17.6
0.716
second-line 
sunitinib
,6
$6
7.8
9.8
0.120 19.0
19.9
0.951
Abbreviations: mPFs, median progression-free survival; mOs, median overall 
survival; VegF, vascular endothelial growth factor.
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first- and second-line treatments. OS was also longer in 
these patients, however, not with a statistical significance 
(Figure 1).
The safety profile of everolimus treatment was mostly 
related with progression and progression-related deaths. 
During the follow-up period of patients (~3½ years, median 
duration of follow-up: 40.5 months), 59% had progression 
of disease. At the end of the follow-up period, 28% of 
patients were alive and 8% of patients were recorded as lost 
to follow-up.
There were 64 different adverse events recorded, and 
in 24 cases, the adverse event was evaluated as possibly 
related to everolimus treatment by the treating physicians 
(Table 4).
Most frequently reported adverse events (5% or higher), 
classified into Medical Dictionary for Regulatory Activi-
ties (MedDRA) system–organ class in decreasing order 
were as follows: gastrointestinal disorders: stomatitis (8%); 
respiratory, thoracic, and mediastinal disorders: pneumonia/
pneumonitis (8%); cardiac disorders: cardiac/cardiopulmo-
nary arrest (7%); and general disorders and administrative 
site conditions: fatigue (5%).
Discussion
Everolimus is currently used as a standard treatment for 
patients who previously progressed on a VEGF-targeted 
therapy in mRCC.6 The results of REnal Cell cancer treat-
ment with Oral RAD001 given Daily (RECORD-1) and 
REACT studies, which used everolimus, showed that it was 
well tolerated in patients with mRCC and was an effective 
and safe second-line treatment for this progressive and lethal 
disease.8,10 In the pivotal study of RECORD-1, the median 
PFS was found to be 4.9 months and the median OS was 
14.8 months.8 The results of our observational study, on the 
other hand, indicate longer durations with everolimus treat-
ment; the median PFS was 8.1 months and the median OS 
was 17.6 months.
The results of our study, which collected data in a real-
life setting in Turkey, proved a better overall response based 
on survival times while showing the efficacy of everolimus 
treatment and presenting an acceptable safety profile. The 
findings of this study confirm that everolimus is a safe and 
effective treatment option as a second- and third-line treat-
ment due to the limited therapeutic efficacy of interferon, 
which is reimbursed as a first-line treatment in Turkey.
Also, in Turkey, due to local reimbursement require-
ments, mTOR inhibitors can be used only after mandatory 
first-line treatment with interferon and subsequent anti-VEGF 
usage in second line. This condition makes mTOR inhibi-
tors as a third-line treatment option in local situation. This 
paper presents preliminary data of everolimus treatment 
from a prospective observational study, which is important 
because it is unique on the basis of its use as a third-line 
treatment option.
The limitation of this study could be its non-interventional 
design that resulted in a higher number of lost to follow-up 
patients, which may have been caused by the nature of rou-
tine clinical practice. An additional limitation of the study 
was the collection of survival data consecutively for first-, 
second- and third-line treatments. For this reason, survival 
data are reflected as an OS for RCC. These limitations also 
might have impacted negatively on the collection of safety 
profile data. Some adverse events that are related with 
everolimus use were not recorded as planned. In this study, 
the most frequently reported adverse event was progression, 
most probably due to treatment with everolimus at much 
Table 4 adverse events
Adverse events Percentage
gastrointestinal disorders
stomatitis 8
respiratory, thoracic, and mediastinal disorders
Pneumonia/pneumonitis 8
cardiac disorders
cardiopulmonary arrest 7
general disorders and administrative site conditions
Fatigue 5
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Figure 1 Progression-free survival with everolimus.
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later stages of the disease. On the other hand, stomatitis and 
pneumonia/pneumonitis were the other two frequent adverse 
events. However, non-infectious pneumonitis (including 
interstitial lung disease) is a class effect of rapamycin deriva-
tives, including everolimus, and has been frequently reported 
in patients taking everolimus. Oral ulcerations and hemato-
logic adverse events were generally expected. Despite term 
differences, the safety profile was evaluated to be consistent 
with the available data in this specific patient group.
As a conclusion, this non-interventional, real-life study 
showed the routine clinical use of everolimus as a third-line 
treatment in a comparatively sizeable number of patients 
with mRCC. Favorable efficacy and safety were shown for 
patients treated with everolimus after at least two previous 
lines of treatment, the first-line being interferon.
Acknowledgment
The authors thank Dr Bülent Yalçın, Yıldırım Beyazit 
University, Clinic of Oncology, Ankara, Turkey and Dr Erdem 
Özdemir, Novartis Oncology, Istanbul, Turkey for careful 
review of this article and supporting conduct of this study.
Disclosure
Dr Esat Ulay is an employee of Novartis. The other authors 
report no conflicts of interest in this work.
References
1. Turkish Ministry of Health. Turkish Cancer Statistics (Türkiye Kanser 
İstatistikleri). Şencan İ, İnce GN, editors. Ankara: Turkish Ministry of 
Health; 2016.
 2. Dhôte R, Pellicer-Coeuret M, Thiounn N, Debré B, Vidal-Trecan G. 
Risk factors for adult renal cell carcinoma: a systematic review and 
implications for prevention. BJU Int. 2000;86(1):20–27.
 3. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence 
of renal cell cancer in the United States. JAMA. 1999;281(17): 
1628–1631.
 4. de Rijke TM, Bellmunt J, Van Poppel H, Marreaud S, Aapro M. 
EORTC-GU group expert opinion on metastatic renal cell cancer. 
Eur J Cancer. 2009;45(5):765–773.
 5. Escudier B, Eisen T, Stadler WM, et al; TARGET Study Group. 
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 
2007;356(2):125–134.
 6. Escudier B, Porta C, Schmidinger M, et al; ESMO Guidelines Com-
mittee. Renal cell carcinoma: ESMO clinical practice guidelines for 
diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Suppl 5): 
v58–v68.
 7. Escudier B, Pluzanska A, Koralewski P, et al; AVOREN Trial inves-
tigators. Bevacizumab plus interferon alfa-2a for treatment of meta-
static renal cell carcinoma: a randomized, double-blind phase III trial. 
Lancet. 2007;370(9605):2103–2111.
 8. Motzer RJ, Escudier B, Oudard S, et al; RECORD-1 Study Group. 
Phase 3 trial of everolimus for metastatic renal cell carcinoma: final 
results and analysis of prognostic factors. Cancer. 2010;116(18): 
4256–4265.
 9. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT 
pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501.
 10. Grunwald V, Karakiewicz PI, Bavbek SE, et al; REACT Study 
Group. An international expanded-access program of everolimus: 
addressing safety and efficacy in patients with metastatic renal cell 
carcinoma who progress after initial vascular endothelial growth factor 
receptor-tyrosine kinase inhibitor therapy. Eur J Cancer. 2012;48(3): 
324–332.
Point your SmartPhone at the code above. If you have a  
QR code reader the video abstract will appear. Or use:
http://youtu.be/O_iMRc9mijY
Video abstract
OncoTargets and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/oncotargets-and-therapy-journal
OncoTargets and Therapy is an international, peer-reviewed, open 
access journal focusing on the pathological basis of all cancers, potential 
targets for therapy and treatment protocols employed to improve the 
management of cancer patients. The journal also focuses on the impact 
of management programs and new therapeutic agents and protocols on 
patient perspectives such as quality of life, adherence and satisfaction. 
The manuscript management system is completely online and includes 
a very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
OncoTargets and Therapy 2018:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1228
Yalçın et al
